bluuebunny/crossref_metadata_2025_split huggingface dataset:
Distrofia muscular de Duchenne: reportes de caso
Authors: Guapi Nauñay Victor Hugo , García Orbe Jorge Renán 
Published: December 2017

<p>La distrofia muscular de Duchenne es una enfermedad muscular grave ligada al cromosoma X que afecta el gen que codifica la distrofina, proteína fundamental para el mantenimiento de la fibra muscular. Se caracteriza por debilidad muscular de inicio en la infancia que sigue un curso progresivo. Sin intervención alguna, los pacientes pierden la marcha antes de la adolescencia y el fallecimiento ocurre en la segunda década de la vida por complicaciones respiratorias o problemas cardiacos. Actualmente no existe tratamiento curativo, pero la terapia con corticoides y el manejo multidisciplinario y ortopédico modifican la historia natural de esta miopatía. En este artículo se presentan dos casos clínicos de niños que presentaron dificultad para realizar actividades físicas vigorosas. Se les diagnosticó distrofia muscular de Duchenne confirmada por creatina-fosfocinasa y electromiografía, con mejoría del cuadro clínico, gracias al tratamiento instaurado.</p><p> </p><p> </p>
Novel Reassortant H3N2 Avian Influenza Virus Isolated from Domestic Ducks in Eastern China in 2016
Authors: Sun Wenqiang , Li Jiaxin , Hu Jiao , Jiang Daxiu , Ge Zhichuang , Xing Chaonan , Wang Xiaoquan , Gu Min , Liu Xiaowen , Hu Shunlin , Liu Xiufan 
Published: December 2017

ABSTRACT
H3 subtype avian influenza virus (AIV) poses a great threat to public health, and so investigating its epidemiology is of great importance. A novel reassortant H3N2 AIV strain was isolated from a live poultry market in eastern China. The strain’s genes originated from H1N1, H3, and H7 AIVs. Thus, the genome information of the H3N2 isolate will help to investigate further the epidemiology of H3 subtype AIVs in China.
Prevention of acute kidney injury through accurate fluid balance monitoring
Authors: Davies Andrew , Srivastava Seema , Seligman William , Motuel Lorraine , Deogan Vardeep , Ahmed Shaza , Howells Nicholas 
Published: November 2017

Acute kidney injury (AKI) is associated with increased patient morbidity, mortality and an extended hospital stay. The financial burden to the National Health Service is high and it can affect up to one in five inpatients. Optimal fluid balance management is essential for the prevention of AKI and this can be particularly challenging in the patient with trauma. Our aim was to reduce the rate of AKI in patients with traumatic injuries in the regional trauma centre.We developed new fluid balance charts and documented how well these were completed. The number of AKI alerts per month was calculated on our pathology system. Scenario training was delivered at handover meetings and an e-learning tool was designed at three levels: healthcare assistants; nurses; and medical staff, dietetics and pharmacists. Educational posters were placed in clinical areas and patient information leaflets produced. Junior doctors were regularly informed of AKI rates on the ward.The number of AKI alerts on our trauma ward declined from 50 in January 2016 to 19 in November 2016. The mean monthly rate of AKI fell 33% following the invention (P<0.001). Completion of fluid balance charts improved; 6 hourly urine output documentation increased from 36% to 68% and running 1 hourly output increased from 80% to 96%. Calculation of total daily fluid balance rose from 12% to 72%, before decreasing to 32%. This highlighted the need for continued encouragement.Improved fluid balance monitoring led to a reduction in the prevalence of AKI in patients admitted to this trauma centre.
Diagnosis of psychosocial risk factors in prevention of low back pain in athletes (MiSpEx)
Authors: Wippert Pia-Maria , Puschmann Anne-Katrin , Arampatzis Adamantios , Schiltenwolf Marcus , Mayer Frank 
Published: November 2017

BackgroundLow back pain (LBP) is a common pain syndrome in athletes, responsible for 28% of missed training days/year. Psychosocial factors contribute to chronic pain development. This study aims to investigate the transferability of psychosocial screening tools developed in the general population to athletes and to define athlete-specific thresholds.MethodsData from a prospective multicentre study on LBP were collected at baseline and 1-year follow-up (n=52 athletes, n=289 recreational athletes and n=246 non-athletes). Pain was assessed using the Chronic Pain Grade questionnaire. The psychosocial Risk Stratification Index (RSI) was used to obtain prognostic information regarding the risk of chronic LBP (CLBP). Individual psychosocial risk profile was gained with the Risk Prevention Index – Social (RPI-S). Differences between groups were calculated using general linear models and planned contrasts. Discrimination thresholds for athletes were defined with receiver operating characteristics (ROC) curves.ResultsAthletes and recreational athletes showed significantly lower psychosocial risk profiles and prognostic risk for CLBP than non-athletes. ROC curves suggested discrimination thresholds for athletes were different compared with non-athletes. Both screenings demonstrated very good sensitivity (RSI=100%; RPI-S: 75%–100%) and specificity (RSI: 76%–93%; RPI-S: 71%–93%). RSI revealed two risk classes for pain intensity (area under the curve (AUC) 0.92(95% CI 0.85 to 1.0)) and pain disability (AUC 0.88(95% CI 0.71 to 1.0)).ConclusionsBoth screening tools can be used for athletes. Athlete-specific thresholds will improve physicians’ decision making and allow stratified treatment and prevention.
Comparison of two low-sensitivity urine pregnancy tests for confirming the success of early medical abortion
Authors: Millar Sarah Louise , Cameron Sharon Tracey 
Published: November 2017

BackgroundWe introduced a single-window low-sensitivity urine pregnancy test (LSPT) to replace a double-window LSPT (both 1000 IU hCG) for self-assessment of the outcome of early medical abortion (EMA) (≤63 days gestation) 2 weeks later. We wished to compare assessment of outcomes of EMA with each LSPT.MethodsA retrospective review of the outcomes of EMA during 10 months' use of the double-window LSPT and the subsequent 10 months' use of the single-window LSPT to compare (i) detection of ongoing pregnancies and (ii) false-positive and invalid results with each LSPT.Results492 and 555 women self-assessed the outcome of their EMA with the double- and single-window LSPTs, respectively. Ongoing pregnancies were uncommon and occurred in 4/1047 women (0.4%). Two of these four women did not conduct a LSPT as they presented before the LSPT was due with scant bleeding or continuing pregnancy symptoms. False-positive LSPT results occurred in 6 (1.2%) and 19 (3.4%) double- and single-window LSPT tests, respectively (P=0.0244). Invalid results were reported in 18 (3.6%) and 6 (1.1%) of double- and single-window LSPT groups, respectively (P=0.01).ConclusionThe introduction of the single-window LSPT has not impacted on the detection of ongoing pregnancy or on contact with the service due to a positive or invalid LSPT. Services could consider use of either LSPT but should also place emphasis on informing women about the clinical signs and symptoms that suggest failed abortion.
Rear-facing versus forward-facing child restraints: an updated assessment
Authors: McMurry Timothy L , Arbogast Kristy B , Sherwood Christopher P , Vaca Federico , Bull Marilyn , Crandall Jeff R , Kent Richard W 
Published: November 2017

ObjectivesThe National Highway Traffic Safety Administration and the American Academy of Pediatrics recommend children be placed in rear-facing child restraint systems (RFCRS) until at least age 2. These recommendations are based on laboratory biomechanical tests and field data analyses. Due to concerns raised by an independent researcher, we re-evaluated the field evidence in favour of RFCRS using the National Automotive Sampling System Crashworthiness Data System (NASS-CDS) database.MethodsChildren aged 0 or 1 year old (0–23 months) riding in either rear-facing or forward-facing child restraint systems (FFCRS) were selected from the NASS-CDS database, and injury rates were compared by seat orientation using survey-weighted χ2tests. In order to compare with previous work, we analysed NASS-CDS years 1988–2003, and then updated the analyses to include all available data using NASS-CDS years 1988–2015.ResultsYears 1988–2015 of NASS-CDS contained 1107 children aged 0 or 1 year old meeting inclusion criteria, with 47 of these children sustaining injuries with Injury Severity Score of at least 9. Both 0-year-old and 1-year-old children in RFCRS had lower rates of injury than children in FFCRS, but the available sample size was too small for reasonable statistical power or to allow meaningful regression controlling for covariates.ConclusionsNon-US field data and laboratory tests support the recommendation that children be kept in RFCRS for as long as possible, but the US NASS-CDS field data are too limited to serve as a strong statistical basis for these recommendations.
Object equivalence: revisiting object equality profiling (an experience report)
Authors: Infante Alejandro , Bergel Alexandre 
Published: December 2017

Modern object-oriented programming languages greatly alleviate the memory management for programmers. Despite the efficiency of garbage collection and Just-In-Time program analyzes, memory still remains prone to be wasted.
A bloated memory may have severe consequences, including frequent execution lags due to a high pressure on the garbage collector and suboptimal object dependencies.
We found that dynamically monitoring object production sites and the equivalence of the produced objects is key to identify wasted memory consumption caused by redundant objects. We implemented optimizations for reducing the memory consumption of six applications, achieving a reduction over 40% in half of the applications without having any prior knowledge of these applications.
Our results partially replicate the results obtained by Marinov and O'Callahan and explore new ways to identify redundant objects.
Abstract A08: Hyperthermia plus radiotherapy in Estrogen receptor positive (ER+) breast cancer; before or after?
Authors: Joveini Zahra , Behrouzkia Zhaleh , Aghdam Reza Zohdi 
Published: December 2017

Abstract
Background: Breast cancer is the most common cancer among women. Hyperthermia is a new cancer treatment modality which is used in addition to other treatments to improve patient's survival. The clinical use of Hyperthermia in the combination of radiotherapy is debatable and shows important technical challenges. But the most challenge in this case is the order of this combination. We aimed to explore that in ER+ breast cancer applying hyperthermia before radiotherapy is better or after it.
Methods and Material: The anti-proliferative activity of Hyperthermia alone and in combination with Radiotherapy in T47D human breast cancer cell line was assessed by the standard 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide (MTT) method. We also used Acridine Orange/ Propidium Iodide fluorescent staining for approving the inhibitory effect. We exposed the cells to 43±0.2°C for 30 minutes in a regular incubator, as Hyperthermia treatment and also exposing into 4Gy Gamma irradiation as Radiotherapy. We applied Hyperthermia before and after Radiotherapy to detect the differences. In two modality treatments the time interval was two hours. Then the viability rates of cells were determined after 24, 48 and 72 hours. All data are expressed as the mean ± standard deviation. We used Kruskal-Wallis and Mann-Whitney for statistical analysis. P-values of less than 0/05 were considered to be statistically significant.
Results: The findings indicated that adding hyperthermia after Radiotherapy showed 43.75±3.86, 40.75±3.09 and 38.25±2.21 viability rate after 24,48 and 72 hours, respectively; while applying it after Radiotherapy showed 47.5±5.12, 45.25±2.21 and 42.75±3.59 viability rate after 24,48 and 72 hours.
Conclusions: It was concluded that in ER-positive breast cancer applying hyperthermia after radiotherapy is more efficient.
Note: This abstract was not presented at the conference.
Citation Format: Zahra Joveini, Zhaleh Behrouzkia, Reza Zohdi Aghdam. Hyperthermia plus radiotherapy in Estrogen receptor positive (ER+) breast cancer; before or after? [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr A08.
Abstract A36: The cytolytic and anti-leukemic potential of ex vivo differentiated NK cells is confined in the CD94 positive population
Authors: Chouaib Salem , Khalifé Nadine Saleh , Hasmim Meriem , Zhang Yanyan , Doldur Manale , Bouhris Jean Henri , Louache Fawzia 
Published: December 2017

Abstract
Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment approach against acute myeloid leukemia (AML). We developed a cytokine-based culture method for the generation of NK cells derived from CD34+hematopoietic progenitor cells (HPC) isolated from fresh umbilical cord blood (UCB). Immuno-phenotyping of ex vivo expanded NK cells showed typical inhibitory and activating NK receptors except for CD16 and the KIR receptors. CB-derived NK cells displayed good cytolytic activity and phenotypic analysis showed that the lytic potential of these ex vivo differentiated NK was associated with their expression level of CD94. We further characterized UCB-derived NK cells by investigating in vivo their toxicity, biodistribution, and anti-leukemic potential. For this purpose, immune deficient mice were engrafted with a patient derived AML strain. We showed that in vivo only the CD94+ NK cells survive and form conjugate with leukemic blasts. The characterization of CD94+ cells and the involvement of CD94 and its ligand in the regulation of these ex vivo differentiated allogenic NK cells lytic activity will be discussed. Our findings suggest that CD94+ NK selection could be a pertinent approach to select highly functional expanded NK cells before therapeutic use.
Citation Format: Salem Chouaib, Nadine Saleh Khalifé, Meriem Hasmim, Yanyan Zhang, Manale Doldur, Jean Henri Bouhris, Fawzia Louache. The cytolytic and anti-leukemic potential of ex vivo differentiated NK cells is confined in the CD94 positive population [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr A36.
Abstract B28: Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men
Authors: Preston Mark , Gerke Travis , Carlsson Sigrid V. , Signorello Lisa , Sjoberg Daniel D. , Markt Sarah C. , Kibel Adam S. , Trinh Quoc-Dien , Steinwandel Mark , Blot William , Vickers Andrew J. , Lilja Hans , Mucci Lorelei A. , Wilson Kathryn M. 
Published: December 2017

Abstract
Background: Baseline prostate specific antigen (PSA) levels measured in midlife predict future prostate cancer mortality among white men. There are minimal data on whether a baseline PSA in African-American men, who experience the highest incidence and mortality of this disease, predicts future aggressive prostate cancer.
Methods: We undertook a nested case-control study among African-American men age 40 to 64 years who gave prediagnostic blood at enrollment in the Southern Community Cohort Study between 2002-2009 and were followed a median of 9 years for cancer incidence and mortality through 2015. Baseline total and free PSA levels were available for 197 prostate cancer cases (55 aggressive cases, Gleason ≥4+3=7, AJCC Stage III or IV, or cancer-specific death) and 569 age-matched controls. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between baseline PSA levels and risk of total and aggressive prostate cancer.
Results: Median PSA among controls was 0.72, 0.80, 0.94, and 1.03 ng/mL for men aged 40 to 49, 50 to 54, 55 to 59, and 60 to 64 years, respectively. Relative risk of total prostate cancer was strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the &gt;90th percentile vs. ≤median were 93.7 (22.5-390) at 40 to 54 years and 77.0 (24.9-238) at 55 to 64 years. Risk of aggressive prostate cancer was also strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the &gt;90th percentile vs. ≤median were 80.8 (14.7 to infinity) at 40-54 years
Citation Format: Mark Preston, Travis Gerke, Sigrid V. Carlsson, Lisa Signorello, Daniel D. Sjoberg, Sarah C. Markt, Adam S. Kibel, Quoc-Dien Trinh, Mark Steinwandel, William Blot, Andrew J. Vickers, Hans Lilja, Lorelei A. Mucci, Kathryn M. Wilson. Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr B28.
Abstract IA12: Targeting DNA repair in cancer therapy
Authors: D'Andrea Alan D. 
Published: December 2017

Abstract
Human cancer cells have genomic instability resulting from germline or acquired defects in DNA repair. One DNA repair pathway - the Fanconi Anemia/BRCA pathway (D'Andrea, A., N Engl J Med 362:1909, 2010) - is defective in many human cancers, including breast, ovarian, and pancreatic neoplasms. Disruption of the FA/BRCA Pathway results in the characteristic chromosome instability and radiation/crosslinker hypersensitivity of these tumors. In general, loss of one DNA repair pathway often leads to hyperdependence on another pathway for tumor cell survival. This hyperdependence offers a unique opportunity for the development of anticancer therapeutics. For instance, FA/BRCA pathway deficient tumors are hyperdependent on Base Excision Repair (BER) and, accordingly, these tumors are hypersensitive to single agent treatment with PARP1 inhibitors, which block BER, or with ATM inhibitors. Our research program is focused on profiling the FA/BRCA pathway and the other five major DNA repair pathways in tumor cells (Kennedy and D'Andrea, JCO 24: 3799, 2006). Each DNA repair pathway has a characteristic biomarker and repairs a specific type of DNA lesion. By profiling these pathways in primary tumor samples with activation-specific antibodies to DNA repair proteins, we have been able (1) to predict the sensitivity of tumors to conventional chemotherapy and radiation (2) to subset tumors for their sensitivity to novel classes of DNA repair inhibitors, (i.e., PARP1, Chk1, ATM, and proteasome inhibitors) and (3) to screen for new small molecule inhibitors of other DNA repair pathways. This combination of novel DNA repair inhibitors, conventional DNA damaging agents, and DNA repair biomarkers offers new opportunities for developing more effective anticancer therapy. In my presentation, I will also discuss novel approaches to sensitizing Triple Negative Breast Cancers (TNBCs) and Ovarian Tumors (OCs) to PARP1 inhibitors. We have previously shown that exposure of these tumors to either a CDK inhibitor or a proteasome inhibitor can block homologous recombination (HR) repair and thereby sensitize the tumor cells to PARP1 inhibitor. The CDK inhibitor/PARP1 inhibitor combination has been examined in orthotopic primary TNBC and OC xenograft models. Finally, we have identified an additional PARP1-dependent DNA repair mechanism in TNBCs and OCs. This pathway is driven by a novel alternative end-joining polymerase, POL. These tumors are hypersensitive to inhibitors of this new pathway, suggesting a new target for DNA repair therapies.
Citation Format: Alan D. D'Andrea. Targeting DNA repair in cancer therapy [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr IA12.
Abstract IA30: CXCL1 is critical for pre-metastatic niche formation and metastasis in colorectal cancer
Authors: DuBois Raymond N. 
Published: December 2017

Abstract
Emerging evidence suggests that once a primary tumor forms it can then influence the development of a supportive metastatic microenvironment, referred to as pre-metastatic niches, in certain distant organs before arrival of metastatic cells. However, the mechanisms underlying the contributions of the primary tumor to pre-metastatic niche formation are not fully understood. Here we demonstrate that colorectal carcinoma cells secrete VEGF-A that stimulates tumor-associated macrophages to produce CXCL1 in the primary tumor. Elevation of CXCL1 in pre-metastatic liver tissue recruits CXCR2-positive myeloid-derived suppressor cells (MDSCs) to form a pre-metastatic niche that ultimately promotes liver metastases. Importantly, we found that pre-metastatic liver-infiltrating MDSCs induce tumor cell survival without involvement of the innate or adaptive immune responses. Our study provides the first evidence we know of showing that primary malignant cell-secreted VEGF-A stimulates tumor-associated macrophages to produce CXCL1 that recruits CXCR2-positive MDSCs to form a pre-metastatic niche which promotes liver metastases. Our findings not only reveal a novel mechanism by which the interactions of malignant cells with their stromal counterparts in the primary tumor contribute to the formation of a pre-metastatic niche that favors tumor cell survival, but also provides a rational for development of CXCR2 antagonists to inhibit or prevent metastatic spread of disease.
Citation Format: Raymond N. DuBois. CXCL1 is critical for pre-metastatic niche formation and metastasis in colorectal cancer [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr IA30.